Source:

Press Release

June 17, 2021
1 min read
Save

Aerie completes enrollment in phase 3 netarsudil trial in Japan

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Aerie Pharmaceuticals has completed enrollment in a phase 3 trial in Japan investigating netarsudil in patients with primary open-angle glaucoma or ocular hypertension, according to a press release.

The randomized, single-masked, multicenter, parallel-group study includes 245 patients who were randomly assigned to receive once-daily netarsudil ophthalmic solution 0.02% or twice-daily ripasudil hydrochloride hydrate ophthalmic solution 0.4%. The superiority study is evaluating the ocular hypotensive efficacy and safety of netarsudil vs. ripasudil over a 4-week period.

“We are pleased that our clinical activities in Japan continue to advance with the completion of enrollment in this first phase 3 clinical trial,” Vicente Anido Jr., PhD, chairman and CEO at Aerie, said in the release. “We expect to conduct a total of three phase 3 clinical trials for Rhopressa in Japan, two 4-week trials and one 12-month safety trial. We currently expect to complete the first phase 3 clinical trial by the end of 2021 and expect to report topline results from the trial shortly thereafter.”

In October 2020, Aerie and Santen announced a deal to develop and market Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) in Japan and other Asian countries.